Key statistics dashboard for Dermata Therapeutics, Inc. (DRMA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Stock Data
| Price | $1.15 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.26 |
| Price / Book | 1.33 |
| P/S | 0.00 |
| P/FCF | -0.10 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 2.81 |
| Quick Ratio | 2.73 |
| Cash Ratio | 2.41 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -14.56 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.87 |
| Cash per share | 1.10 |
| FCF per share | -2.03 |
| Tangible Book Value per share | 0.87 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Related companies: ARTL · ATXI · CARM · ELAB · GTBP · LIPO · PBM
Explore sector: Healthcare · Biotechnology
More sections of DRMA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks